Literature DB >> 20213712

Statistical models for heart rate correction of the QT interval.

Arne Ring1.   

Abstract

The analysis of QT interval data is now an essential part of the assessment of drug safety. As the QT interval is inversely associated with heart rate, an appropriate correction must be applied in order to evaluate QT data in clinical trials. The aim is to characterize changes in QT interval at a standard heart rate, taking into account the correlation between these two variables to adjust for heart rate changes during the course of the trial. It has been shown that the relationship between the RR interval (=1/heart rate) and the QT interval is highly variable between individuals but stable over time within each individual.Many mathematical models have been developed to describe the QT-RR relationship. However, there has been less emphasis on the derivation of suitable statistical models that account for the multilevel structure of the ECG data.An important example is the interpretation of the so-called population-specific heart rate corrections, which are based on data pooled from different subjects. Often, simple regression techniques are used to quantify the population correction, disregarding the subject level and leading to biased parameter estimates. Instead, population-based corrections that account for individual intercepts should be used, in order to distinguish within-subject-effects from between-subject effects. Therefore, population-specific corrections cannot be derived solely from the cross-sectional data. The impact of the different statistical models is illustrated by data from the baseline periods of six clinical QT studies.

Mesh:

Year:  2010        PMID: 20213712     DOI: 10.1002/sim.3791

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.

Authors:  S Y A Cheung; J Parkinson; U Wählby-Hamrén; C D Dota; Å M Kragh; L Bergenholm; T Vik; T Collins; C Arfvidsson; C E Pollard; H K Tomkinson; B Hamrén
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-05-07       Impact factor: 2.745

2.  The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.

Authors:  Arne Ring; Andreas Port; E Ulrike Graefe-Mody; Ivette Revollo; Mario Iovino; Klaus A Dugi
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

3.  Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.

Authors:  Arne Ring; Karin Rathgen; Joachim Stangier; Paul Reilly; Andreas Clemens; Jeffrey Friedman
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

4.  The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

Authors:  Arne Ring; Tobias Brand; Sreeraj Macha; Kerstin Breithaupt-Groegler; Gudrun Simons; Beate Walter; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-04-24       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.